TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12906979

Group type: EXPERIMENTAL
Intervention: Prolonged monitoring with an implantable loop recorder with one-year monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional testing with external loop recorder, tilt, and electrophysiologic testing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Crossover from conventional testing to monitoring
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Monitoring followed by tilt and EP testing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional testing followed by monitoring
Number of subjects: 60
Study: 10485722

Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg/day) and Vitamin E (400 IU/day)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Vitamin C and E
Number of subjects: 283
Study: 8608485

Group type: EXPERIMENTAL
Intervention: Continuous infusion 5-fluorouracil (5-FU) at doses ranging from 200-1100 mg/m2/day for 4 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Brachytherapy with radioactive gold (Au198) seed placement
Number of subjects: 25
Study: 1768563

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg) + Indomethacin (75 mg) + Ketotifen (1 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg) + Indomethacin (75 mg)
Number of subjects: 10
Study: 6816343

Group type: EXPERIMENTAL
Intervention: Tablets and capsules taken with 100 ml of water
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tablets and capsules taken with 25 ml of water
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tablets and capsules taken while recumbent
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Tablets and capsules taken while standing
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Small tablets
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Liquid forms of medication (suspensions)
Number of subjects: 121
Study: 31230798

Group type: EXPERIMENTAL
Intervention: Silver-foam dressing (Mepilex® Ag)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Porcine xenograft dressing (EZderm®)
Number of subjects: 58
Study: 29367198

Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy (30 minute session)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Information booklet (control)
Number of subjects: 441
Study: 26797227

Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT) group treatment program
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 44
Study: 24888199

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atorvastatin (all doses)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atorvastatin (higher doses)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 100
Study: 23259716

Group type: EXPERIMENTAL
Intervention: Strength training group
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Endurance training group
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Combined strength + endurance training group
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Diet and physical activity recommendations group
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: All groups (combined)
Number of subjects: 239
Study: 21186930

Group type: EXPERIMENTAL
Intervention: 1.8 ml/kg energy drink
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 3.6 ml/kg energy drink
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 5.4 ml/kg energy drink
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 80

Group type: COMPARATOR
Intervention: No drink
Number of subjects: 80
Study: 17592240

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone (IVT) 4 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham injection (natural course)
Number of subjects: 25
Study: 16300417

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study: 12379552

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate and salmeterol combination (FSC)
Number of subjects: 691
Study: 10080557

Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate injections every 2 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluphenazine decanoate injections every 6 weeks
Number of subjects: 50
Study: 7546872

Group type: EXPERIMENTAL
Intervention: 48 hours' strict bed rest
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (encouraged to remain mobile)
Number of subjects: 42
Study: 2284579

Group type: EXPERIMENTAL
Intervention: Hydrophobic material (Sorbact; n = 1,213)
Number of subjects: 2441

Group type: COMPARATOR
Intervention: 0.5% chlorhexidine in 70% ethanol (n = 1,228)
Number of subjects: 2441

Group type: EXPERIMENTAL
Intervention: Hydrophobic material (Sorbact)
Number of subjects: 2441

Group type: COMPARATOR
Intervention: 0.5% chlorhexidine in 70% ethanol
Number of subjects: 2441
Study: 7104425

Group type: EXPERIMENTAL
Intervention: Slightly deviant stimuli (one lower and one higher in pitch)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Widely deviant auditory stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deviant stimuli (both types)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endogeneous brain waves
Number of subjects: 0
Study: 28504857

Group type: EXPERIMENTAL
Intervention: Hysteroscopic niche resection
Number of subjects: 103

Group type: COMPARATOR
Intervention: Expectant management (Control)
Number of subjects: 103
Study: 27197855

Group type: COMPARATOR
Intervention: Glucose alone (25 g)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Whey protein (10 g) + glucose (15 g)
Number of subjects: 21
Study: 24526291

Group type: EXPERIMENTAL
Intervention: emWave intervention (4-8 sessions)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 27
Study: 23584716

Group type: EXPERIMENTAL
Intervention: MOVE! weight management program (6 months, includes individual and group sessions)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control condition (basic information about diet and exercise every month)
Number of subjects: 109
Study: 20501735

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.1 mmol/kg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.1 mmol/kg)
Number of subjects: 96
Study: 18426828

Group type: EXPERIMENTAL
Intervention: Fine needle aspirate thyroglobulin (FNATg) measurement in DTC patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fine needle aspirate thyroglobulin (FNATg) measurement in benign FNA cytology
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fine needle aspirate thyroglobulin (FNATg) measurement in non-informative cytology
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fine needle aspirate thyroglobulin (FNATg) measurement in negative controls
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fine needle aspirate thyroglobulin (FNATg) measurement in positive controls
Number of subjects: 34
Study: 16652071

Group type: EXPERIMENTAL
Intervention: Gabapentin (peak dose of 2,400 mg/d over 20 weeks)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Gabapentin (1,800 and 2,400 mg/day)
Number of subjects: 39
Study: 12795579

Group type: EXPERIMENTAL
Intervention: Enhanced content telephone counseling tailored to the stage of cessation (motivation, self-efficacy, negative mood)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic content telephone counseling primarily consisting of support
Number of subjects: 0
Study: 10831474

Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Imipramine treatment
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Early-onset major depressive disorder
Number of subjects: 531

Group type: COMPARATOR
Intervention: Late-onset major depressive disorder
Number of subjects: 531

Group type: COMPARATOR
Intervention: Never-occurring major depressive disorder
Number of subjects: 531
Study: 9336134

Group type: EXPERIMENTAL
Intervention: Accelerated Hyperfractionated (AH) radiotherapy (1.6 Gy b.i.d. to a total dose of 54.4 Gy)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Accelerated Fractionation (AF) of 30 Gy in 10 daily fractions
Number of subjects: 445

Group type: COMPARATOR
Intervention: RPA class I patients (KPS of 70 or more, controlled primary tumor, <65 years of age, brain metastases only) in AF arm
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: RPA class I patients (KPS of 70 or more, controlled primary tumor, <65 years of age, brain metastases only) in AH arm
Number of subjects: 445
Study: 1540455

Group type: EXPERIMENTAL
Intervention: Pulse oximeter data and alarms available (group I)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pulse oximeter data and alarms unavailable (group II)
Number of subjects: 200
Study: 3887172

Group type: EXPERIMENTAL
Intervention: Amitriptyline (mean dose: 57.8 mg per day, max 75 mg per day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30024193

Group type: EXPERIMENTAL
Intervention: Therapists' affiliative tendencies and time elapsed in therapy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Bond aspect of the therapeutic alliance
Number of subjects: 109
Study: 27670567

Group type: EXPERIMENTAL
Intervention: Bowel prep group
Number of subjects: 32

Group type: COMPARATOR
Intervention: No bowel prep group
Number of subjects: 32
Study: 25395314

Group type: EXPERIMENTAL
Intervention: Chemotherapy (6 × 3-weekly cycles FE₁₀₀C)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Endocrine therapy (letrozole 2.5 mg, daily for 18-23 weeks)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 44
Study: 24330675

Group type: EXPERIMENTAL
Intervention: Dyspeptic patients (PADYQ score ≥ 6)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-dyspeptic patients (PADYQ score < 6)
Number of subjects: 50
Study: 20146793

Group type: EXPERIMENTAL
Intervention: Supervised Nordic walking twice a week for eight weeks
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Unsupervised Nordic walking with one-hour instruction followed by home advice for eight weeks
Number of subjects: 151

Group type: COMPARATOR
Intervention: Advice to remain active
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Supervised Nordic walking
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Unsupervised Nordic walking
Number of subjects: 151
Study: 17459096

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate 200 mg/day (F group)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily (O group)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Combination of orlistat and fenofibrate (OF group)
Number of subjects: 89
Study: 16189259

Group type: EXPERIMENTAL
Intervention: Telepaque (iopanoic acid), 500 mg/d orally for 7 days
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 131I therapy after Telepaque
Number of subjects: 200

Group type: COMPARATOR
Intervention: Carbimazole, 30-40 mg daily until euthyroid followed by 131I
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Telepaque (iopanoic acid)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Carbimazole
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups after mean follow-up of 11 years
Number of subjects: 200
Study: 12499994

Group type: EXPERIMENTAL
Intervention: Nucleotide-fortified infant formula (NF)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control formula (CF)
Number of subjects: 336
Study: 10376390

Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler 400 micrograms/day
Number of subjects: 227

Group type: COMPARATOR
Intervention: Beclomethasone MDI 800 micrograms/day
Number of subjects: 227
Study: 8885674

Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine (1st dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine (2nd dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine (3rd dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (1st dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (2nd dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (3rd dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine (local reactions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (local reactions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine (systemic side effects)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (systemic side effects)
Number of subjects: 0
Study: 2065925

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg.kg‐1.day‐1 for 1 month)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (15 mg.kg‐1.day‐1 for 1 month)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (during weight-reduction period)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (during weight-reduction period)
Number of subjects: 20
Study: 6587751

Group type: EXPERIMENTAL
Intervention: Verapamil (Isoptin) 120 mg X 3 for four weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31522334

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.03%
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 46

Group type: COMPARATOR
Intervention: Tacrolimus and Pimecrolimus (combined analysis)
Number of subjects: 46
Study: 29752248

Group type: EXPERIMENTAL
Intervention: Web-based lifestyle intervention for hypertensive patients
Number of subjects: 264
Study: 27236379

Group type: EXPERIMENTAL
Intervention: BPD‐DS with a 200‐cm common channel (study group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: BPD‐DS with a 100‐cm common channel (control group)
Number of subjects: 72
Study: 25121612

Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI) at 10°C for 10 min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Active recovery (low‐intensity cycling) for 10 min
Number of subjects: 10
Study: 22927454

Group type: EXPERIMENTAL
Intervention: intermittent dosing schedule of aerosolized ribavirin
Number of subjects: 50

Group type: COMPARATOR
Intervention: continuous dosing schedule of aerosolized ribavirin
Number of subjects: 50
Study: 21548546

Group type: EXPERIMENTAL
Intervention: On-pump myocardial revascularization
Number of subjects: 120

Group type: COMPARATOR
Intervention: Off-pump myocardial revascularization
Number of subjects: 120
Study: 16286540

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (30-microg, once weekly, intramuscular)
Number of subjects: 36
Study: 14562858

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 0
Study: 10371118

Group type: EXPERIMENTAL
Intervention: Chemotherapy (PVM: 80 mg/m2 Cisplatin on day 1, 2-3 mg/m2 Vindesine on day 1 and/or day 8, 8 mg/m2 Mitomycin C on day 1, followed by 400 mg/day UFT orally for 1 year)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Chemotherapy (PVM)
Number of subjects: 225
Study: 8664018

Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia (WBC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cold blood cardioplegia (CBC)
Number of subjects: 40
Study: 2054273

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 6185020

Group type: EXPERIMENTAL
Intervention: Dimetapp (DIM)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Brompheniramine maleate (BPM)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Phenylephrine hydrochloride (PEH)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 98
Study: 31630182

Group type: EXPERIMENTAL
Intervention: Entonox
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 25
Study: 29783900

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg PO daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg PO daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 28544171

Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 153
Study: 26541070

Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 0
Study: 24503429

Group type: EXPERIMENTAL
Intervention: Warfarin prescribed according to predicted warfarin dose based on VKORC1 and CYP2C9 genotypes
Number of subjects: 220

Group type: COMPARATOR
Intervention: Warfarin prescribed according to empirical clinician estimates
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Study group
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Average predicted dose for stable dose patients
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Average effective dose for stable dose patients
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Difference between average predicted dose and actual dose
Number of subjects: 220
Study: 21411056

Group type: EXPERIMENTAL
Intervention: Peer-assisted learning led by fourth‐year medical students
Number of subjects: 60

Group type: COMPARATOR
Intervention: Resident-assisted learning led by obstetrics and gynecology residents
Number of subjects: 60
Study: 18791585

Group type: EXPERIMENTAL
Intervention: Wand
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional syringe
Number of subjects: 40
Study: 16386259

Group type: EXPERIMENTAL
Intervention: STAEST spread (1.93-1.98g/day) for 10 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: STEEST spread (1.93-1.98g/day) for 10 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (spread without sterols or stanols for 20 weeks)
Number of subjects: 39
Study: 16191240

Group type: EXPERIMENTAL
Intervention: Donepezil (acetylcholinesterase inhibitor), dosage and duration not specified
Number of subjects: 1219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1219
Study: 10969126

Group type: EXPERIMENTAL
Intervention: Ventilation tubes (VT group)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Watchful waiting (WW group)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Comprehensive language improvement
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Expressive language development
Number of subjects: 187
Study: 8853805

Group type: EXPERIMENTAL
Intervention: Immunoadsorption therapy utilizing Prosorba column
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunoadsorption therapy
Number of subjects: 0
Study: 1346539

Group type: EXPERIMENTAL
Intervention: Timoptic (timolol maleate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betagan (levobunolol hydrochloride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betoptic (betaxolol hydrochloride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilopine Gel (pilocarpine hydrochloride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Miostat (carbachol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iopidine (apraclonidine hydrochloride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diamox (acetazolamide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 6345176

Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 6

Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 6
Study: 28872380

Group type: EXPERIMENTAL
Intervention: Low-intensity training (HA-L)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-intensity training (HA-H)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (usual training in thermoneutral conditions)
Number of subjects: 19
Study: 27161956

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (reading newspapers or watching television)
Number of subjects: 41
Study: 25005782

Group type: EXPERIMENTAL
Intervention: WPH + CHO supplementation with ECC resistance training
Number of subjects: 24

Group type: COMPARATOR
Intervention: CHO supplementation with ECC resistance training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ECC resistance training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CONC resistance training
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both WPH + CHO and CHO supplementation
Number of subjects: 24
Study: 21374756

Group type: EXPERIMENTAL
Intervention: Prophylactic percutaneous endoscopic gastrostomy (PEG)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Clinical praxis (control group)
Number of subjects: 134
Study: 20868961

Group type: EXPERIMENTAL
Intervention: Mapleson D circuit
Number of subjects: 18

Group type: COMPARATOR
Intervention: bag‐valve‐mask device
Number of subjects: 18
Study: 18651608

Group type: EXPERIMENTAL
Intervention: 750 mg nabumetone tablet formulation
Number of subjects: 12
Study: 17121035

Group type: EXPERIMENTAL
Intervention: Qingre Yulin Decoction (QYD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antibiotic plus vitamin E (Control)
Number of subjects: 60
Study: 12110823

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10036560

Group type: EXPERIMENTAL
Intervention: Patient education intervention
Number of subjects: 0
Study: 7750315

Group type: EXPERIMENTAL
Intervention: Leukocyte specific filter
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard blood filter
Number of subjects: 32
Study: 1369947

Group type: EXPERIMENTAL
Intervention: Acute stage of the disease
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Recovery period
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 6996538

Group type: EXPERIMENTAL
Intervention: Pantomography
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard 'four view' mandibular series
Number of subjects: 17